EPAS1 and pancreatic neuroendocrine tumor: This finding led to the development of a targeted inhibitor of HIF-2α, belzutifan (MK 6482, PT-2977), now approved for use in patients with VHL disease-associated renal cell carcinomas, pancreatic neuroendocrine tumors and CNS hemangioblastomas not requiring immediate surgery [8–10].